Clinical Trial Update: Camrelizumab(SHR-1210) Combined With GEMOX in Patients With Relapsed or Refractory Hodgkin Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating camrelizumab (SHR-1210) plus GEMOX in relapsed or refractory Hodgkin lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• Camrelizumab (camrelizumab)
• GEMOX (gemcitabine + oxaliplatin)

Snippet

Sponsor: Peking University | Conditions: Hodgkin Lymphoma | Phase 2 | Status: UNKNOWN